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Abstract
Current epidemic obesity levels apply great medical and financial pressure to the strenuous economy of obesity-prone
cultures, and neuropeptides involved in body weight regulation are regarded as attractive targets for a possible treatment
of obesity in humans. The lateral hypothalamus and the nucleus accumbens shell (AcbSh) form a hypothalamic-limbic
neuropeptide feeding circuit mediated by Melanin-Concentrating Hormone (MCH). MCH promotes feeding behavior via
MCH receptor-1 (MCH1R) in the AcbSh, although this relationship has not been fully characterized. Given the AcbSh
mediates reinforcing properties of food, we hypothesized that MCH modulates motivational aspects of feeding. Here we
show that chronic loss of the rat MCH-precursor Pmch decreased food intake predominantly via a reduction in meal size
during rat development and reduced high-fat food-reinforced operant responding in adult rats. Moreover, acute AcbSh
administration of Neuropeptide-GE and Neuropeptide-EI (NEI), both additional neuropeptides derived from Pmch, or
chronic intracerebroventricular infusion of NEI, did not affect feeding behavior in adult pmch+/+ or pmch2/2 rats. However,
acute administration of MCH to the AcbSh of adult pmch2/2 rats elevated feeding behavior towards wild type levels. Finally,
adult pmch2/2 rats showed increased ex vivo electrically evoked dopamine release and increased limbic dopamine
transporter levels, indicating that chronic loss of Pmch in the rat affects the limbic dopamine system. Our findings support
the MCH-MCH1R system as an amplifier of consummatory behavior, confirming this system as a possible target for the
treatment of obesity. We propose that MCH-mediated signaling in the AcbSh positively mediates motivational aspects of
feeding behavior. Thereby it provides a crucial signal by which hypothalamic neural circuits control energy balance and
guide limbic brain areas to enhance motivational or incentive-related aspects of food consumption.
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Introduction
The Melanin-Concentrating Hormone (MCH) precursor (Pmch)
is predominantly expressed in neurons of the lateral hypothalamus
(LHA) and the incerto hypothalamic area (sometimes referred to
as zona incerta), which project throughout the brain [1,2,3]. Pmch
processing generates glycine-glutamic acid (NGE), glutamic acid-
isoleucine (NEI), and MCH [4]. MCH, a 19-amino acid cyclic
peptide, is a key regulator of food intake and metabolism; Pmch
mRNA is upregulated after fasting [5,6], Pmch-deficient (pmch2/2)
rodents are hypophagic, lean, and have a decreased body weight
as compared to wild type siblings [7,8,9], whereas Pmch
overexpression results in hyperphagia and obesity [10]. Finally,
intracerebroventricular (ICV) administration of MCH increases
feeding [6,11,12,13,14,15,16].
In rodents MCH binds to MCH receptor-1 (MCH1R),
which is present at high levels in limbic regions
[17,18,19,20,21]. For example, the nucleus accumbens shell
(AcbSh) modulates orexigenic activity of MCH [15,21]. Mch1r-
deficient mice are lean, hyperphagic, and hyperactive [22,23],
central blockade of MCH1R lowers body weight and food
intake through several mechanisms [24,25,26], and acute
central MCH1R-blockade decreases high-fat food-reinforced
operant responding [27].
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Dopamine is an important neurotransmitter in the nucleus
accumbens (NAc), and absence of MCH-mediated signaling in
mice increased NAc dopamine release and NAc dopamine
receptor levels [28,29,30,31]. MCH1R is expressed in AcbSh
medium spiny neurons (MSNs) [21] and coexpressed with
dopamine D1 and D2 receptors (D1R and D2R, respectively)
[32]. Finally, reductions of AcbSh neuronal excitability, either by
administration of MCH, an AMPA receptor antagonist, or a
GABA receptor agonist all stimulate baseline-feeding behavior
[33,34,35,36,37,38], supporting a cellular excitability hypothesis of
AcbSh-mediated feeding behavior [39].
The above findings link the hypothalamic orexigenic MCH
circuit with neuronal AcbSh signaling activity that influences
behavioral responses to rewarding stimuli including food and
drugs of abuse. Furthermore, these findings have also generated
interest from the pharmaceutical industry, as functional blockade
of MCH1R in humans could be a potential target for the
treatment of obesity.
In this study we use a recently generated rat knockout model [8]
to investigate how chronic loss of Pmch in the rat affects
motivational or incentive-related aspects of feeding behavior.
Results
Meal structure analysis in pmch2/2 rats during rat
development
A previous study showed that chronic loss of Pmch in the rat
resulted in hypophagia as compared to wild-type rats [8]. To
investigate in more detail which elements of feeding behavior are
changed during the observed hypophagia, we performed a meal
structure analysis (parameters: body weight, food intake, total meal
duration, average meal duration, meal frequency, average intermeal
interval, average meal size, rate of eating, and satiety ratio) in pmch+/+
and pmch2/2 rats at PNDs 40, 58, 70, 84, and 98 (Figs. 1A – I).
The statistical analyses revealed a genotype effect for body weight,
food intake, average meal size, rate of eating, and satiety ratio
Figure 1. Meal structure analysis in pmch+/+ and pmch2/2 rats. (A) Body weight, (B) food intake, (C) total meal duration, (D) average meal
duration, (E) meal frequency, (F) average intermeal interval, (G) average meal size, (H) rate of eating, and (I) satiety ratio in pmch+/+ and pmch2/2 rats at
postnatal days [PND] 40, 58, 70, 84, and 98. Body weight, food intake, average meal size, and rate of eating are predominantly decreased in pmch2/2
rats, while satiety ratios are predominantly increased in pmch2/2 rats (1, P,0.05, WT vs. HOM; *P,0.05, **P,0.005, ***P,0.001, Students’ t-test; n = 8 per
group). Data are shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g001
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(Table S1). In addition, a time x genotype interaction was observed
for body weight and average meal size (Table S1).
Although some parameters were affected at individual time
points, robust effects after chronic loss of Pmch in the rat were only
observed for body weight, food intake, and average meal size.
Because average meal size is markedly affected, but meal duration
is not, this translates to changes in rate of eating and satiety ratio.
Decreased acute hyperphagia in pmch2/2 rats when
newly presented with high fat diet
To investigate whether the hypophagia in pmch2/2 rats (this
study and [8]) results from perturbed food-induced reward
signaling, we measured acute hyperphagia of adult pmch+/+ and
pmch2/2 rats, grown on a standard semi-high protein (SHP) diet,
when newly offered a palatable high-fat (HF) diet. In addition,
acute hypophagia in response to newly offered SHP diet to adult
rats grown on an HF diet was also investigated.
Home-cage food intake during basal days (days 1–5) was
decreased in pmch2/2 rats as compared to pmch+/+ rats on both
SHP and HF diet (P,0.01, by Student’s t-test; Figs. 2A and B).
Statistical comparison of baseline levels revealed a significant effect
of diet (F(1,25) = 12; P,0.005) and of genotype (F(1,25) = 29; P,0.001),
but no diet x genotype interaction (F(1,25) = 0.07; P=0.79). This
suggests that pmch2/2 rats respond equally to the intrinsic
rewarding properties of the HF diet as compared to pmch+/+ rats.
However, statistical analysis for acute hyperphagia, when offered a
HF diet for the first time, revealed a significant effect of time
(F(6,77) = 41; P,0.001), of genotype (F(1,13) = 16; P,0.005), and a time
x genotype interaction (F(6,77) = 41; P,0.005; Fig. 2A). Although
both pmch+/+ and pmch2/2 rats increased their caloric intake
significantly during the first day on HF diet (F(1,13) = 191.9;
P,0.001), the increase in caloric intake showed an increased trend
in pmch+/+ rats as compared to pmch2/2 rats (17266% versus
15266%, respectively; P=0.060, Student’s t-test).
When adult pmch+/+ and pmch2/2 rats, raised on an HF diet, were
switched to SHP diet, the statistical analysis for acute hypophagia
revealed significant effects of time (F(4,46) = 5; P,0.005) and genotype
(F(1,12) = 14; P,0.005), but no time x genotype interaction (F(4,77) = 0.5;
P=0.73; Fig. 2B). Both pmch+/+ and pmch2/2 rats reduced their
caloric intake during the first day on SHP diet (F(1,12) = 8; P,0.05).
However, during acute hypophagia the decrease was equal between
pmch+/+ and pmch2/2 rats (1468% decrease versus 1767%
decrease, respectively; P=0.74, Student’s t-test).
Loss of Pmch in the rat reduces high-fat food-reinforced
operant responding
As pmch2/2 rats demonstrated hypophagia, we set out to
investigate if pmch2/2 rats have a decreased incentive, or
motivation, for HF food-reinforced operant responding. Adult
food-limited male pmch+/+ and pmch2/2 rats were tested in a self-
administration paradigm where rats could lever press for 45% HF
pellets (Fig. 3A).
During the training phase (FR1 schedule) rats were given 3 hr
access to the pellets every other day. Statistical analysis for total
active-lever presses during training revealed a significant effect of
time (F(4,71) = 4; P,0.05), but not of genotype (F(1,18) = 1; P=0.25) and
a trend for the time x genotype interaction (F(4,71) = 2; P=0.08; Fig. 3B).
The average number of pellets earned per training sessions was
stable over time and statistical analysis revealed no significant effect
of time (F(7,128) = 1; P=0.70) or of genotype (F(1,18) = 1; P=0.40), and
also no time x genotype interaction (F(7,128) = 1; P=0.43; Fig. 3B).
Statistical analysis for total inactive-lever presses revealed a
significant effect of time (F(5,84) = 11; P,0.001), but not of genotype
(F(1,18) = 0.2; P=0.66) and no time x genotype interaction (F(5,84) = 0.7;
P=0.61; Fig. 3B). Time-course analysis of the mean pellets earned
within the training sessions revealed a significant effect of time
(F(2,37) = 93; P,0.001) and of genotype (F(1,22) = 12; P,0.005), but no
time x genotype interaction (F(2,37) = 0.1; P=0.84; Fig. 3C). Mean
cumulative pellet intake per training session was decreased in
pmch2/2 rats as compared to pmch+/+ rats (P,0.005, Student’s t-test;
Fig. 3C, inset). Timeout active-lever presses per pellet earned during
training revealed a significant effect of time (F(3,47) = 14; P,0.001),
but not of genotype (F(1,14) = 2; P=0.24) and no time x genotype
interaction (F(3,47) = 3; P=0.07; Fig. 3D). This observation mirrors
the progressive escalation of timeout active lever presses across
sessions (data not shown), which has been previously reported
[27,40,41,42,43].
During the progressive ratio (PR) phase [44] rats were given 3
hr access to the pellets every other day. Statistical analysis for
breakpoint values during PR revealed a significant effect of time
(F(3,54) = 8; P,0.001), a trend effect of genotype (F(1,18) = 4;
P=0.052), but no time x genotype interaction (F(3,54) = 0.5;
Figure 2. Acute hyperphagia in pmch2/2 rats when newly presented with HF diet. (A) Adult pmch+/+ and pmch2/2 rats grown on standard
SHP diet showed acute hyperphagia when newly presented with HF diet. However, acute hyperphagia was attenuated in pmch2/2 rats (17266%
increase in pmch+/+ rats compared to 15266% increase in pmch2/2 rats; ***P,0.001 versus SHP days1–5, repeated-measures ANOVA with special
contrast analysis; n = 7–8 per group). (B) Adult pmch+/+ and pmch2/2 rats grown on HF diet showed acute hypophagia when newly presented with
SHP diet. Acute hypophagia was equal between genotypes (1468% decrease in pmch+/+ rats as compared to 1767% decrease in pmch2/2 rats;
*P,0.05 versus HF days1–5, repeated-measures ANOVA with special contrast analysis; n = 6–8 per group). Data are shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g002
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Figure 3. Pmch2/2 rats show decreased HF food-reinforced operant responding for 45% fat pellets. (A) Experimental timeline for HF
food-reinforced operant responding paradigm. (B) Number of total active-lever presses (squares), total inactive-lever presses (circles), and total
number of pellets (triangles) during training sessions over 12 alternating days (one 3 hr session per day, every other day). (C) Mean pellets earned
during 12 training sessions (total per 15-min bin time course) or per 3 hr (inset). (D) Total number of time-out (TO) presses per pellet during training
sessions. (E) Breakpoint values of progressive ratio (PR) sessions over 4 alternating days (one 3 hr session per day, every other day), and mean
breakpoint value of the last 3 PR sessions. Number of total active-lever presses (squares) and total inactive-lever presses (circles) during extinction
sessions before (F) cue-induced (22 extinction sessions), (G) pellet-induced (9 extinction sessions), or (H) yohimbine-induced (14 extinction sessions)
reinstatement (R, reinstatement session) of food seeking. Inset shows R session enlarged (n = 10 per group). 1, P,0.05, 11, P,0.005, WT vs. HOM,
repeated-measures ANOVA; *P,0.05, **P,0.005, Students’ t-test. Data are shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g003
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P=0.72; Fig. 3E). Mean cumulative breakpoint value of the last
three sessions was decreased in pmch2/2 rats as compared to
pmch+/+ rats (P,0.05, Student’s t-test; Fig. 3E).
After PR, rats were tested on a FR1 schedule for 4 additional 3-
hr sessions (data not shown) followed by 22 3-hr extinction
sessions. Statistical analysis for total active-lever presses during
these 22 extinction sessions revealed a significant effect of time
(F(21,378) = 46; P,0.001) and of genotype (F(1,18) = 7; P,0.05), and a
time x genotype interaction (F(21,378) = 4; P,0.001; Fig. 3F). Cue-
induced reinstatement did not differ between genotypes (P=0.12;
Student’s t-test; Fig. 3F, inset). Nine additional extinction sessions
preceded pellet-induced reinstatement. Statistical analysis for total
active-lever presses during these 9 extinction sessions revealed a
significant effect of time (F(5,90) = 8; P,0.001) and of genotype
(F(1,18) = 14; P,0.005), but no time x genotype interaction (F(5,90) = 1;
P=0.43; Fig. 3G). Pellet-induced reinstatement did not differ
between genotypes (P=0.12; Student’s t-test; Fig. 3G, inset).
Fourteen additional extinction sessions preceded yohimbine (an
a2-adrenergic receptor antagonist and pharmacological stressor)-
induced reinstatement. Statistical analysis for total active-lever
presses during these 14 extinction sessions revealed no significant
effect of time (F(6,112) = 2; P=0.16) or of genotype (F(1,18) = 1;
P=0.38), and no time x genotype interaction (F(6,112) = 1; P=0.21;
Fig. 3H). Yohimbine-induced reinstatement did not differ between
genotypes (P=0.99; Student’s t-test; Fig. 3H, inset). Total inactive-
lever presses during extinction and reinstatement were very low,
did not differ between genotypes, and did not change over time
(P.0.1; Figs. 3F, G, and H).
Chronic ICV administration of NEI does not affect body
weight or food intake
Pmch2/2 rats lack the three neuropeptides derived from the
Pmch precursor, NGE, NEI and MCH [4,8]. To date, NGE does
not appear to have a biological function, whereas NEI has been
implicated in dopamine system modulation in several brain
regions [45]. Therefore, we administered NEI or aCSF ICV in
pmch+/+ and pmch2/2 rats for 26 days using osmotic minipumps
and measured body weight and food intake.
Administration of NEI did not affect body weight growth in
either pmch+/+ or pmch2/2 rats as compared to pmch+/+ or pmch2/2
rats with aCSF administration, as statistical analysis for body
weight growth revealed a significant effect of time (F(4,81) = 113;
P,0.001; Fig. 4A). However, neither the effect of genotype or
treatment, nor the interaction between time and genotype, or treatment,
nor the triple interaction between genotype, time, and treatment was
significant (P.0.1). Average home-cage food intake, as measured
during 7 days before osmotic pump implantation (basal week) or
during days 7–13 (week 2) or days 20–26 (week 4) after osmotic
pump implantation, was also not affected by NEI administration
in either pmch+/+ or pmch2/2 rats, as statistical analysis for food
intake revealed a significant effect of time (F(2,38) = 21; P,0.001)
and of genotype (F(3,19) = 17; P,0.001; Fig. 4B). However, neither
the effect of treatment, nor the interaction between time and genotype,
or treatment, nor the triple interaction between genotype, time, and
treatment was significant (P.0.1; Fig. 4B). Average water intake, as
measured during the basal week, week 2, or week 4, was not
affected by NEI administration in either pmch+/+ or pmch2/2 rats
(data not shown).
MCH administration to the AcbSh of pmch2/2 rats
rescues feeding behavior to wild-type levels
Acute administration of MCH (1 mg/side) or a MCH1R-agonist
(5 mg/rat) to the AcbSh of wild-type rats increases food intake
[15,21]. Therefore we investigated whether bilateral administra-
tion of MCH (1 mg [419pmol] per side) to the AcbSh of pmch2/2
rats would elevate home-cage feeding behavior to wild-type levels
during the first 4 hr of the dark phase. We also tested if bilateral
co-administration of NEI and NGE (1 mg each [691 and 509pmol,
respectively] per side) to the AcbSh of nondeprived pmch2/2 rats
would affect home-cage feeding behavior.
Statistical analyses revealed a significant effect of time
(F(2,72) = 174; P,0.001), of treatment (F(2,36) = 5; P,0.05) and a time
x genotype interaction (F(2,72) = 6; P,0.01; Figs. 5A and B). In
addition, both the effect of genotype and the interaction between time
and treatment showed a trend (P=0.09 and P=0.08, respectively),
while no significant effect was observed for the interaction between
Figure 4. Chronic ICV administration of NEI in pmch2/2 rats does not affect body weight or food intake. (A) Changes in body weight
growth during 26-day ICV aCSF infusion in pmch+/+ (n = 10) and pmch2/2 (n = 6) rats or 26-day ICV NEI infusion in pmch+/+ (n = 3) and pmch2/2 (n = 4)
rats (A). Rat body weight during operation (day 0) was set at 100%. (B) Average food intake (expressed as kcal/day) during aCSF or NEI infusion in
pmch+/+ and pmch2/2 rats before minipump implantation (basal week), or during administration (week 2 or 4 as indicated in A); 1, P,0.005, WT aCSF
vs. HOM aCSF; {, P,0.05, WT NEI vs. HOM aCSF;#, P,0.001, WT aCSF vs. HOM NEI; ,ˆ P,0.005, WT NEI vs. HOM NEI, repeated-measures ANOVA). Data
are shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g004
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genotype and treatment (P.0.1) or the triple interaction between
genotype, time, and treatment (P.0.1). Post hoc analysis revealed
significant effects of MCH-treatment as compared to aCSF-
treatment (P,0.05), but no significant effect for NEI/NGE-
treatment (P.0.1). Within time-point analysis revealed increased
food intake in MCH-treated pmch+/+ rats as compared to aCSF-
treated pmch+/+ rats after 1 hr and 4 hr (P,0.05, Student’s t-test;
Fig. 5A), decreased food intake in aCSF-treated pmch2/2 rats as
compared to aCSF-treated pmch+/+ rats after 4 hr (P,0.05,
Student’s t-test; Figs. 5A and B), decreased food intake in aCSF-
treated pmch2/2 rats as compared to MCH-treated pmch+/+ rats
after 2.5 hr and 4 h (P,0.05 and P,0.005, respectively, Student’s
t-test; Fig. 5A), and decreased food intake in NEI/NGE-treated
pmch2/2 rats as compared to aCSF-treated pmch+/+ rats after 4 hr
(P,0.05, Student’s t-test; Fig. 5B). However, food intake in MCH-
treated pmch2/2 rats did not differ significantly from aCSF-treated
pmch+/+ rats after 4 hr (106612% in pmch2/2 rats; P=0.68,
Student’s t-test; Fig. 5A). After 22 hr, food intake in aCSF-treated
pmch2/2 rats was decreased as compared to aCSF-treated pmch+/+
rats (8961% in pmch2/2 rats; P,0.05, Student’s t-test; data not
shown).
Finally, after 22 hr food intake of MCH-treated rats did not
differ significantly from food intake of aCSF-treated rats with the
same genotype (data not shown).
Chronic loss of Pmch in the rat affects the dopamine
system
Several studies in Pmch- or Mch1r-deficient mice have shown
increased dopamine release and increased dopamine receptor
levels [28,29,30,31], suggesting that the dopamine system in the
NAc of pmch2/2 rats might also be affected.
First we investigated if NAc dopamine release differs between
genotypes using challenged conditions in neurochemical experi-
ments (i.e. using electric stimulation), revealing that electrically
evoked dopamine release ex vivo was elevated in acute coronal NAc
brain slice preparations from untreated ad libitum-fed pmch2/2 rats
compared to untreated ad libitum-fed pmch+/+ rats (Fig. 6A).
Moreover, sample treatment with GBR12909, a highly specific
dopamine transporter (DAT) inhibitor, increased the difference in
evoked NAc dopamine release even further (12967% at basal
levels vs. 14468% with GBR12909 treatment as compared to
pmch+/+ rats; Fig. 6A). Statistical analysis revealed an effect of
genotype (F(1,44) = 52; P,0.001), treatment (F(1,44) = 112; P,0.001),
and a genotype x treatment interaction (F(1,44) = 7; P,0.05; Fig. 6A).
This suggested that NAc DAT protein levels were increased in
pmch2/2 rats, as was recently shown for pmch2/2 mice [29].
Radioactive ligand-binding analysis revealed that NAc DAT
protein expression was indeed increased in pmch2/2 rats, both in
the nucleus accumbens core (AcbCo; 11866%) and in the AcbSh
(12365%; Fig. 6B). Similar results were observed for the caudate
putamen (CPu) in pmch2/2 rats (Figs. 6A and B), whereas pmch 2/2
mice did not show a difference in CPu DAT levels [29].
As ex vivo electrically evoked dopamine release was increased in
the NAc of pmch2/2 rats, we studied relative gene expression of a
subset of genes, involved in dopaminergic storage capacity or
signaling, in the NAc of adult pmch+/+ and pmch2/2 rats. Relative
expression of D1R (Drd1a), D2R (Drd2), GluR1 (Gria1), DARPP32
(Darpp32), tyrosine hydroxylase (Th), and 5-hydroxytryptamine
(serotonin) receptor 2c (Htr2c) was unchanged between genotypes
(Fig. 6C). However, both relative expression of VMAT2 (Vmat2)
and Synapsin1 (Syn1) showed an increased trend in pmch2/2 rats
compared to pmch+/+ rats (P=0.067 and P=0.069 by Students’
t-test, respectively; Fig. 6C).
Vmat2 is responsible for transmitter loading of synaptic vesicles
[46], is preferentially expressed in the CNS [47,48], and increased
expression of Vmat2 increases NAc dopaminergic storage capacity
[49]. The G protein subunits, Go2 and Gao2, are involved in the
negative regulation of VMAT2 activity [50], whereas the MCH-
MCH1R system signals via Gi/o [38,51,52,53,54]. Synapsin 1
controls the fraction of synaptic vesicles available for release [55],
and elevated Syn1 expression can thereby increase the efficiency of
dopamine release observed in pmch2/2 rats in this study.
Therefore, our data suggest that loss of the negative modulation
of MCH-mediated signaling via Gi/o might affect vesicle dynamics
in the presynaptic terminal.
Finally, we investigated if these presynaptic adaptations result in
elevated extracellular dopamine levels in vivo. However, basal in
vivo extracellular AcbSh dopamine levels measured using classical
microdialysis in fasting rats did not differ between genotypes
(Fig. 6D).
Figure 5. Acute AcbSh administration of MCH elevates home-cage feeding behavior in pmch2/2 rats towards wild-type levels. (A)
Food intake (expressed in kcal) measured 1, 2.5, and 4 hr after aCSF or MCH administration (1 mg/side) in the AcbSh of pmch+/+ and pmch2/2 rats at
the beginning of the dark phase. (B) Food intake measured 1, 2.5, and 4 hr after aCSF administration or co-administration of NEI and NGE (1 mg each/
side) in the AcbSh of pmch+/+ and pmch2/2 rats at the beginning of the dark phase (n = 6–8 per group). *P,0.05, **P,0.005, Student’s t-test. Data are
shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g005
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Discussion
Results from the present study confirm an important role for
MCH-mediated signaling in the positive control of appetitive
behavior. Chronic loss of Pmch changed meal structure dynamics
during rat development and adulthood, and decreased HF food-
reinforced operant responding in adult rats. In addition, chronic
ICV administration of NEI or acute co-administration of NEI and
NGE in the AcbSh of pmch2/2 rats did not affect body weight
regulation, whereas acute administration of MCH in the AcbSh of
pmch2/2 rats elevated home-cage food intake towards wild-type
levels. Finally, using biochemical and molecular assays we show
that chronic loss of Pmch affects striatal dopamine system
dynamics.
A robust reduction in meal size in pmch2/2 rats during
development and adulthood appears consistent with the finding
that pharmacological blockade of MCH1R in wild-type DIO-rats
decreased home-cage meal size but not meal frequency [56].
Moreover, the study by Kowalski et al. suggests that a reduced
meal size is a direct effect of absent MCH-mediated signaling,
resulting in the hypophagia observed in pmch2/2 rats (this study
and [8]) or after acute MCH1R-blockade in wild-type DIO rats
[56]. However, loss of Pmch in the rat also affects energy
expenditure [8]. Thus, a more detailed longitudinal metabolic
analysis is necessary to identify additional parameters that might
be responsible for changed body weight dynamics during chronic
loss of Pmch in the rat.
MCH immunoreactive fibers innervate nucleus of the solitary
tract (NTS) regions [57]. Therefore, Pmch-deficiency potentially
removes the inhibitory effect of MCH on glutamate transmission
between primary vagal afferents and NTS neurons [58],
decreasing meal size and caloric intake. However, 4th ventricle
MCH injections had no effect on caloric intake [58]. Thus, it is
unlikely that a reduced meal size results from a lack of MCH
signaling at the level of the brainstem. However, we cannot
exclude that satiety factors integrated outside the brain stem are
affected in our rat model. This leaves the arcuate nucleus,
paraventricular nucleus, dorsomedial nucleus, and the AcbSh as
primary effecter sites of MCH function [15,21,58,59]. Finally,
changes in ‘natural’ and ‘unnatural’ reward-related neurochem-
istry and behavior observed here and in other studies
[21,28,29,30,31], and the intensive crosstalk between hypotha-
Figure 6. Striatal dopamine system dynamics in pmch2/2 rats. (A) Electrically evoked control dopamine release is similar between genotypes
in the CPu, but is increased in the NAc of pmch2/2 rats compared to pmch+/+ rats. Electrically evoked dopamine release in both the CPu and NAc of
pmch2/2 rats is increased compared to pmch+/+ rats after treatment with GBR12909, a highly specific dopamine transporter (DAT) inhibitor. Data is
shown in comparison to wild-type control release as 100% (dotted line; *P,0.005, Students’ t-test; n = 4 per group). (B) DAT expression is increased in
the CPu, AcbCo, and the AcbSh of pmch2/2 rats compared to pmch+/+ rats. Brain areas are indicated on an atlas section from Paxinos and Watson [72]
(*P,0.05, Students’ t-test; n = 8–11 per group). (C) Relative gene expression of a subset of genes involved in dopaminergic storage capacity and
dopamine signaling in the NAc of adult pmch+/+ and pmch2/2 rats revealed an increased trend of Vmat2 and Syn1 in pmch2/2 rats compared to
pmch+/+ rats (P= 0.067 and P= 0.069 by Students’ t-test, respectively; n = 8–9 per group). (D) Average basal extracellular AcbSh dopamine levels did
not differ between fasting pmch+/+ and pmch2/2 rats (n = 7 per group). Data are shown as mean 6 S.E.M.
doi:10.1371/journal.pone.0019600.g006
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lamic and striatal brain regions indicate that the AcbSh is a likely
converging site to exert the orexigenic action of MCH.
As overeating of palatable foods is driven by hedonic factors, the
blunted overeating in pmch2/2 rats as compared to pmch+/+ rats
when newly presented with an HF diet suggest a dysregulated
mesolimbic regulation of feeding behavior. In addition, no
difference in hypophagia was observed when rats were switched
from an HF diet to a SHP diet, indicating that a potential
mesolimbic functional dysregulation in pmch2/2 rats is only
observed under acute reward stimulatory conditions. Pmch2/2
mice, bred on a C57BL6 background, demonstrated no acute
overfeeding during a similar paradigm but, surprisingly, also
displayed no hypophagia when fed ad libitum [29].
Pmch2/2 rats showed decreased HF food-reinforced operant
responding during FR1 sessions. Our observations align with
recent findings that acute MCH1R-blockade reduces HF food-
reinforced operant responding, supporting the hypothesis that
MCH1R-antagonism accelerates satiety mechanisms after the
initiation of food intake, as speculated by Nair et al. [27].
Moreover, changes in satiety mechanisms do not appear to be
short-term as for instance with Cholecystokinin, which acts within
15 minutes [60], but it seems to be a more gradual effect. This
notion is supported by our observations that loss of Pmch had no
clear effect on pellet intake during the first 30 minutes of self-
administration during FR1 sessions or on food intake during the
first 2.5 hours of the dark phase of ad libitum-fed aCSF-treated
pmch+/+ and pmch2/2 rats in the AcbSh infusion experiment. In
sum, our data suggest that MCH-mediated signaling is not crucial
for the initiation of feeding, but it rather amplifies food intake or
decreases satiety after the initiation of feeding.
Pmch2/2 rats demonstrated decreased breakpoint values during
PR sessions. The breakpoint value can be seen as a measure for
the rewarding value of the reinforcer [61], and breakpoints were
found to decrease with decreasing nutritional value of a food
reward whereas they increase during food deprivation [61,62].
This indicates that 45% HF pellets have a decreased rewarding
value in pmch2/2 rats. Finally, chronic loss of Pmch did not robustly
affect cue-, pellet-, or yohimbine-induced reinstatement of food
seeking. These findings complement recent observations that acute
blockade of MCH1R-mediated signaling plays a minimal role in
pellet-priming, cue-, or yohimbine-induced reinstatement [27].
Pmch encodes for NGE, NEI, and MCH [4], and our rat model
lacks all three neuropeptides [8]. Here we show that chronic ICV
administration of NEI had no effect on body weight regulation in
either pmch+/+ or pmch2/2 rats. This observation strengthens
earlier findings that acute ICV NEI administration did not affect
food intake in wild-type rats, nor did it affect the orexigenic effect
of ICV MCH administration [11]. Furthermore, acute co-
administration of 1 mg NEI and 1 mg NGE in the AcbSh of
pmch+/+ and pmch2/2 rats also did not affect home-cage feeding
behavior. In sum, our results indicate that loss of either NEI- or
NGE-mediated signaling does not contribute to the aberrant
feeding behavior in pmch2/2 rats, implicating an important role for
MCH.
Acute administration of MCH or a MCH-analog to the AcbSh
of wild-type rats increased food intake [15,21], suggesting that
administration of MCH to the AcbSh of pmch2/2 rats could
elevate food intake towards wild-type levels. First, acute AcbSh
administration of 1 mg MCH elevated, albeit not significantly, food
intake in wild-type rats. Furthermore, we show that acute
administration of 1 mg MCH to the AcbSh of pmch2/2 rats
indeed elevated home-cage feeding behavior towards wild-type
levels. These observations indicate that administration of 1 mg
MCH in the AcbSh of pmch2/2 rats is sufficient to temporarily
elevate food intake towards wild-type levels. Finally, it confirms the
important role for the AcbSh in MCH-mediated control of feeding
behavior.
Several studies have shown that loss of MCH-mediated
signaling affects striatal dopamine system dynamics
[28,29,30,31]. Although a direct correlation between dysregulated
striatal dopamine function and hypophagia after loss of MCH-
mediated signaling has not yet been demonstrated, it is tempting to
speculate that there is a link between the two observations. Here
we observed that chronic loss of Pmch in the rat resulted in
increased presynaptic dopaminergic release capacity, increased
DAT levels in the NAc of pmch2/2 rats, and an increased trend in
NAc gene expression of Syn1 and Vmat2. Finally, basal extracel-
lular AcbSh dopamine levels were not changed in fasting rats,
indicating that under non-stimulated conditions, pmch2/2 rats do
not appear to have an increased dopamine tone. However, in our
set-up, increased AcbSh DAT levels might potentially mask an
increased dopamine tone. Although our data clearly indicate that
the striatal dopamine system is affected in the rat after chronic loss
of Pmch, the physiological relevance of these changes remain to be
studied in more detail.
Pmch2/2 rats are hypophagic [8], but the exact mechanism
behind the hypophagia is still unknown. Recently it has been
shown that MCH administration to the AcbSh of rats affects the
phosphorylation state of GluR1ser845, reduces surface expression of
GluR1-containing AMPA receptors (AMPARs), decreases ampli-
tude of AMPAR-mediated synaptic events, suppresses action
potential firing MSNs through K+-channel activation, and reduces
neuronal cell firing in freely moving rats [21,38]. Therefore, it is
possible that loss of MCH-mediated signaling affects striatal
glutamatergic signaling and dopamine function, but that the latter
effect is not causal to the observed hypophagia in Pmch-deficient
rodents. However, this has to be studied in more detail. Moreover,
in addition to the direct effects on AcbSh neuronal excitability,
MCH might also indirectly influence neuronal excitability of other
brain areas, such as the medial ventral pallidum and the ventral
tegmental area, via its effects on the AcbSh [38,39]. Finally, loss of
MCH-mediated signaling in brain areas such as the paraven-
tricular nucleus and dorsomedial nucleus can also contribute to the
phenotypes observed in this study, and therefore also remain to be
studied in more detail.
An alternative to the conclusion that chronic loss of Pmch
directly influences motivational aspects of feeding is that Pmch
deletion could result in a defect in hypothalamic brain develop-
ment resulting in hypophagia and a changed metabolic rate. This
argument is formally difficult to exclude; however, no gross
neuroanatomical defects were observed in brain sections from rats
lacking Pmch. Furthermore, direct evidence for a pharmacological
etiology is provided by the modulation of feeding behavior by
acute or chronic administration of MCH, MCH-analogues, or
MCH1R-antagonists, as described above.
MCH-mediated signaling between the LHA and the NAc has
been implicated in communicating the hedonic, or rewarding
aspects of feeding [63]. We here show that chronic loss of Pmch
affects motivational aspects to obtain food and thus provides a
crucial signal with which hypothalamic neural circuits controlling
energy balance guide frontal brain areas to shift motivation
towards food. Without MCH-mediated signaling, motivation away
from food appears to prevail. In addition, others and we show that
chronic loss of MCH-mediated signaling affects striatal dopamine
function [28,29,30,31], an ability that is shared by other LHA
factors [64,65]. Incorrect control of food intake is one of the
hallmarks for developing or maintaining obesity. Therefore, the
development of an anti-obesity treatment based on central
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MCH1R-antagonism could potentially be a way to reverse obesity
by changing the motivational aspects of feeding behavior.
Materials and Methods
Ethics statement
The Animal Care Committees of the Royal Netherlands
Academy of Arts and Sciences, the University Medical Center
Utrecht, and the Free University of Amsterdam approved all
animal procedures according to Dutch legal ethical guidelines.
Animals
Pmch+/+ and pmch2/2 rats, on a Wistar background [8], were
socially housed (2 per cage) unless noted otherwise in a temperature-
and humidity-controlled room (2162uC and 60% relative humid-
ity) under a 12 hr light-dark cycle (lights on at 6 AM). Standard diet
(semi-high protein [SHP]: RM3, 27% protein, 12% fat, 62%
carbohydrate, 3.33 kcal/g AFE, SDS, Witham, United Kingdom)
and water was available ad libitum unless noted otherwise. Rats used
for the self-administration experiments were housed under a
reversed 12 hr light-dark cycle with standard diet (lights on at 6
PM; Teklan Global 2016, 22% protein, 12% fat, 66% carbohy-
drate, 3.0 kcal/g AFE, Harlan, Horst, The Netherlands) and water
available ad libitum. Rats used in the AcbSh infusion experiments
were on a 12 hr light-dark cycle (lights on at 5 AM) and also fed
Teklan Global 2016. Only male rats were used in the present study.
Genotyping
Rats were genotyped using the KASPar SNP Genotyping
System (KBiosciences, Hoddesdon, UK) as described before [8].
Rats were genotyped around postnatal day (PND) 21, and
genotypes were reconfirmed after experimental procedures were
completed.
Meal structure analysis
Rats were placed individually into monitoring cages, and allowed
to acclimatize for 2 days. Body weight, food and water intake were
measured daily. Water and SHP diet were available ad libitum. Meal
structures were determined from 2 consecutive days during each
experimental time point using data collected by Scales (Department
Biomedical Engineering, UMC Utrecht, the Netherlands). This
program records the weight of food hoppers in the home cage
automatically every 12 seconds, as well as the amount of licks from
water bottles. A meal was defined as an episode of food intake with a
minimal consumption of 1 kilocalorie (0.3 g of chow). Two
consecutive meals were separated by a minimal interval of 5
minutes [66,67]. Data analysis using a longer minimal interval did
not result in appreciable changes of the results. Parameters (food
intake, total meal duration, average meal duration, meal frequency,
average intermeal interval, average meal size, rate of eating, and
satiety ratio) were measured at PNDs 40, 58, 70, 84, and 98. If not in
the monitoring cages, rats were housed together (2 per cage) in their
home cage. The intermeal interval was defined as the interval
between the last response of a meal to the first response of the next
meal. Rates of eating were calculated by dividing each meal size by
its respective duration. Finally, the satiety ratio, an index of the non-
eating time (i.e., satiety) produced by each gram of food consumed,
was calculated as the average intermeal interval divided by the
average meal size [68].
Acute hyperphagia assay
Adult rats ($12 weeks old) were housed individually and after 3
days of acclimatizing, food intake was measured for 5 consecutive
days. On day 6, rats received high-fat (HF) diet (45%-AFE, 20%kcal
protein, 45%kcal fat, 35%kcal carbohydrates, 4.54 kcal/g AFE,
SDS, Witham, United Kingdom) for 4 consecutive days. To
measure acute hypophagia, rats were grown up on HF diet after
weaning, and were newly presented with standard SHP diet at an
adult age ($12 weeks old) with the same set-up as described above.
Drugs
Yohimbine-HCl (Sigma-Aldrich, Zwijndrecht, The Nether-
lands) was dissolved in sterile saline solution (NaCl, 0.9%).
MCH (Bachem), NEI (Bachem), and NGE (Bachem) were
dissolved in artificial CSF (aCSF) immediately before use.
Food self-administration
The food self-administration experiments were conducted in
standard, ventilated, and sound-attenuating operant conditioning
test chambers (Med Associates Inc.). The chambers were fitted
with a dim red house light and two small levers separated 15 cm
from each other. Water was available ad libitum. A pellet receptacle
was placed in between the levers. One lever was designated as
‘active’; lever pressing on this lever resulted in the delivery of one
45 mg pellet containing 45% fat and 34% carbohydrate (F05879,
5.85 kcal/g AFE; Bioserv, San Diego, CA). At the same time a cue
light above the active lever was turned on for 5 sec and 6 sound
clicks were produced during 3 sec (compound cue). Lever presses
on the inactive lever were monitored, but were without
consequences. A 15 sec time-out period immediately followed
each pellet delivery during which lever pressing was without
consequences. A computer interfaced to the chambers was used
for equipment operation and data collection. Med PC IV software
(Med Associates Inc.) was used to analyze data.
Acquisition (FR1) and progressive ratio (PR) schedules
Adult ($12 weeks old) pmch+/+ rats weighing between 330–
350 g and pmch2/2 rats weighing between 280–300 g at the
beginning of the experiment were used. Home-cage food intake
was measured during 4 days before the start of the experiment,
and all rats received approximately 80% of their regular food
intake during the self-administration paradigm. Body weight and
food intake were measured daily during the course of the study.
Acquisition phase sessions (3 hr duration, with cues: cue light on
for 5 sec, 6 sound clicks during 3 sec) commenced after 7 days of
acclimation to the animal facility and were performed between 10
AM and 1 PM. Rats were allowed to self-administer pellets during
12 daily sessions on an intermittent (1 day) fixed ratio 1 (FR1)
schedule of reinforcement. After the FR1 schedule, rats were
allowed to self-administer pellets on a progressive ratio (PR)
schedule during 4 intermittent (1 day) sessions (3 hr duration, with
cues: cue light on for 5 sec, 6 sound clicks during 3 sec). The
successive increase in number of lever presses required to obtain a
pellet delivery was calculated by the following equation: Response
ratio = (5e(0.2*reward number))25, rounded to the nearest integer [44].
This equation produced the following sequence of required lever
presses: 1, 2, 4, 6, 9, 12, 15, 20, 35, 40, 50, 62, 77 etcetera. The
final ratio attained was defined as the animal’s breakpoint.
Extinction phases and reinstatement
After the PR sessions, rats were allowed to self-administer pellets
at an FR1 schedule for 4 intermittent (1 day) sessions (3 hr
duration, with cues: cue light on for 5 sec, 6 sound clicks during 3
sec). Rats then entered an extinction phase of 22 consecutive daily
sessions (1 hr duration, no reward, no cues). After all rats showed
stable extinction values (,10 active responses, 5 consecutive
sessions), rats were tested for cue-induced relapse (1 hr duration,
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no reward, 1 cue series at start of session and the ability to respond
for the compound cue on an FR1 schedule). Rats then entered an
extinction phase of 9 consecutive daily sessions during which
responding for the cues was extinguished (1 hr duration, no
reward, with cues). After all rats showed stable extinction values
(,10 active responses, 5 consecutive sessions) rats were tested for
pellet-induced relapse (1 hr duration, no reward, 1 pellet at start of
session, with cues). Following 14 additional extinction sessions rats
were tested for yohimbine-induced relapse (1 hr duration, no
reward, yohimbine [2 mg/kg, 1 ml/kg, intraperitoneal, 30 min
prior to start of session], with cues). Yohimbine is an a2-adrenergic
receptor antagonist that induces stress-like responses [69].
Chronic intracerebroventricular NEI administration
Body weight, food-, and water intake of individually housed rats
were measured for 8 days (PNDs 86–94). At PND 94, rats were
anesthetized with isoflurane, and received one dose of Temgesic
(0.05 mg/kg subcutaneous; Schering-Plough, Utrecht, the Nether-
lands). Average body weight at PND 94 was 400 g for pmch+/+ rats
and 323 g for pmch2/2 rats. A sterile brain infusion cannula (28-
gauge; Brain infusion kit 1; Alzet, Palo Alto, CA) was stereotaxically
implanted into the left third ventricle. When a flat skull position was
used, the stereotaxic coordinates were 0.9 mm caudal to the
bregma, 1.5 mm lateral to the midline, and 3.5 mm (pmch+/+ rats) or
3.0 mm (pmch2/2 rats) from the surface of the skull. The cannulae
were fixed to the skull with dental cement. The infusion cannula was
connected to an osmotic minipump (Pump model 2002, Alzet, Palo
Alto, CA) that was filled with aCSF. The osmotic pumps were
placed under the dorsal skin of the neck and connected to the ICV
cannula using plastic tubing (length 9 cm; i.d. 0.69 mm; o.d.
1.14 mm). At the start of the study each cannula was filled with
aCSF. After distribution into matched experimental and control
groups, pmch+/+ rats and pmch2/2 rats received a minipump filled
with either aCSF (0.5 ml/hr) or NEI (dissolved in aCSF; 8 mg/rat/
day). Body weight, food-, and water intake were then recorded every
two days for 13 days. After 13 days, at PND 107, all rats received a
new mini pump under isoflurane anesthesia. Subsequently, body
weight, food-, and water intake were recorded every two days for
another 13 days. At the end of all experiments, the animals were
sacrificed and the position of the ventricular cannula assessed
following the injection of 150 ml of Evans blue dye (2 mg/ml) and
visual examination of brain slices. Only parameters recorded from
animals with correctly positioned cannulae were included in the
results. Body weight at PND 94 was set as 100%. Average food and
water intake was calculated for PNDs 86–93 (basal week), PNDs
100–106 (week 2), or PNDs 114–120 (week 4).
AcbSh surgery
Adult pmch+/+ and pmch2/2 rats ($15 weeks old) received a
guide cannula (Plastics One) in the AcbSh bilaterally, as described
before [21]. After surgery, the rats were allowed to recover for 7
days, followed by daily manipulation and habituation to the
injection procedure for 3 days.
AcbSh microinjection procedure
AcbSh microinjection procedure was performed as described
before [21]. Tubing was coated with 2% BSA solution to minimize
loss of MCH to the tubing. Reagent was resuspended in aCSF
immediately before use.
AcbSh feeding behavior assay
On a test day, food was removed at 4 PM, and the rats were
allowed to remain in their home cage until the drug or vehicle
control was injected into the AcbSh using a full Latin square
design (aCSF, 1 mg MCH per side, or 1 mg NEI and 1 mg NGE
per side). After the injection, the rats were returned to their home
cage, and 1 hr later they were allowed full access to their chow.
The experiment started at the beginning of the dark cycle (5 PM),
and food and water intake were measured for 1, 2.5, 4, and 22 hr
after the start of the dark cycle. Each test session was separated by
3 days. No evidence of order or carryover was observed in the
Latin square design.
AcbSh histology
At the end of the experiment, rats were given an overdose of
sodium-pentobarbital (200 mg/kg, intraperitoneal) and were
intracardially perfused with 60 ml 4% paraformaldehyde solution.
Vibratome sections (35 mm) were cut to determine the correct
location of the guide cannulae. Only data from rats with two
correctly placed cannulae were included.
Neurochemical analysis
Adult rats ($12 weeks old) were decapitated and the caudate
putamen (CPu) and nucleus accumbens (NAc) were rapidly
dissected from the coronal brain slices. Samples (0.36
0.362 mm) were prepared using a McIlwain tissue chopper,
incubated and superfused essentially as described before [70].
Samples were washed twice with Krebs-Ringer bicarbonate
medium (in mM; NaCl, 121; KCL, 1.87; KH2PO4, 1.17;
MgSO4, 1.17; NaHCO3, 25; CaCl2, 1.22 and D2(+)-glucose,
10), followed by preincubation for 15 min in this medium in a
constant atmosphere of 95% O2-5% CO2 at 37uC. After
preincubation, the samples were washed rapidly with the Krebs-
Ringer and incubated for 15 min in 2.5 mL of this medium
containing 5 mCi [3H]dopamine in an atmosphere of 95% O2-
5% CO2 at 37uC with or without 6 mM GBR-12909 (dopamine
reuptake inhibitor; Sigma-Aldrich, Zwijndrecht, the Nether-
lands). As the CPu and the NAc have a dense noradrenergic
innervation, 3.6 mM desipramine (3-isobutyl-1-methyl-xantine
[DMI]; Sigma, St. Louis, MO, USA) was added to the medium
of these brain structures to prevent accumulation of [3H]dopa-
mine in noradrenergic nerve terminals. After labeling, the
samples were washed rapidly and transferred to a chamber of
the superfusion apparatus (approximately 4 mg tissue in 0.2 mL
volume) and superfused (0.2 mL/min) with medium gassed with
95% O2-5% CO2 at 37uC. In each observation, neurotrans-
mitter release from samples of pmch+/+ and pmch2/2 rats was
studied simultaneously. After 40 min of superfusion (t= 40 min),
the superfusate was collected as 10-min samples. Neurotrans-
mitter release was induced by exposing the samples to electrical
biphasic block-pulses (1 Hz, 4 ms at 30 mA) for 10 min at
t= 50. The radioactivity remaining at the end of the experiment
was extracted from the tissue with 0.1N HCl. The radioactivity
in superfusion fractions and tissue extracts was determined by
liquid scintillation counting. The efflux of radioactivity during
each collection was expressed as a percentage of the amount of
radioactivity in the slices at the beginning of the respective
collection period. The electrically evoked release of neurotrans-
mitter was calculated by subtracting the spontaneous efflux of
radioactivity from the total overflow of radioactivity during
stimulation and the next 10 min. A linear decline from the 10-
min interval before to that 20–30 min after the start of
stimulation was assumed for calculation of the spontaneous
efflux of radioactivity. The evoked release was expressed as
percentage of the content of radioactivity of the samples at the
start of the stimulation period.
MCH, Motivation, and Feeding
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19600
Autoradiographic DAT assay
Cryostatic coronal sections (10 mm) through mid-striatum
from adult rats ($12 weeks old) were preincubated (20 min,
20uC) in 50 mM Tris-HCl 120 mM NaCl (pH 7.4), then 1 hr in
fresh buffer containing 10 pM RTI-55 (2200 Ci/mmol; Perkin
Elmer) and 1 mM Citalopram and Nisoxetine (Sigma-Aldrich,
Zwijndrecht, the Netherlands), with nonspecific binding defined
with 100 mM GBR-12909 (Sigma-Aldrich, Zwijndrecht, the
Netherlands). Slides were washed twice for 10 min in fresh
buffer (4uC), dipped in ice-cold deionised water, airflow dried,
exposed to tritium-sensitive film for 5 days with tritium
standards, photodeveloped, and analyzed using NIH freeware
ImageJ.
NAc mRNA expression
Adult rats ($12 weeks old) were sacrificed during the early
afternoon. The NAc was rapidly dissected and snap-frozen in
liquid nitrogen. Total RNA was isolated using a Trizol method
and RNA quantity and quality was assessed using a Nanodrop
ND-1000 spectrophotometer (Thermo-Scientific, Wilmington,
DE, USA). cDNA was synthesized from 1 mg of total RNA using
a RetroScript kit (Applied Biosystems, Nieuwerkerk a/d IJssel, NL)
as described by the manufacturer, and diluted in MQ (1:2 for Th
and Vmat2; 1:8 for all other genes). Gene expression was quantified
with a 7900 HT Real-Time PCR machine (ABI Prism). Primers
for Cyclophilin, Drd1a, Drd2, GluR1, DARPP32, Th, Vmat2, Syn1, and
Htr2c were designed using SciTools PrimerQuest (IDT; primers
shown in Table S2). Primers were optimized to amplify cDNA but
not genomic DNA and to generate a single PCR product. PCR
efficiency was between 80% and 120%. In general, 2 ml template,
10 mM primers, and 5 ml SYBRGreen Mix (Applied Biosystems)
was used in a 10 ml PCR reaction. Thermocycler conditions
comprised an initial holding stage at 50uC for 2 min followed by
95uC for 3 min followed by a PCR program consisting of 95uC for
30 sec and 60uC for 30 sec for 40 cycles. Samples were run in
triplicates. To control for input, Cyclophilin was run on the same
plate and used as a control gene. Calculations were performed by
a comparative method (2.02DDCt), taking the efficiency of the PCR
into account (1.8–2.2). All experiments were repeated twice after a
new cDNA synthesis reaction. Average pmch2/2 rat gene
expression from the three experiments is expressed as a percentage
of average pmch+/+ gene expression.
AcbSh microdialysis surgery
Rats were anesthetized using isoflurane (2.5%, 400 ml/min
N2O, 600 ml/min O2). Lidocaine (10% m/v) was used for local
anesthesia. The animals were fixed in a stereotaxic frame and
unilaterally implanted with a stainless steel guide cannula (8 mm)
aimed at the right AcbSh according to previously described
procedures [49,71]. The following coordinates were used:
anteroposterior +10.2 mm; lateral 20.8 mm; dorsoventral
26.0 mm [72]. The anteroposterior coordinate is relative to the
interaural line; the lateral coordinate is relative to the midline
suture and the dorsoventral coordinate is relative to the skull
surface. The cannula was fixed onto the skull and anchored with
dental cement and stainless steel screws. The guide cannula
contained an inner cannula to prevent infections and occlusions.
The rats were allowed to recover from surgery for at least 7 days in
Plexiglas microdialysis cages (25625635 cm) for the rest of the
experiment. On 3 consecutive days, prior to the start of the
microdialysis experiment, each rat was gently picked up and lifted
above the top of the home cage in order to habituate them to
handling.
Microdialysis procedure
A detailed description of the microdialysis procedure has been
published elsewhere [49]. In short, a dialysis probe (type A-I-8-02,
outer diameter: 0.22 mm, 50,000 molecular-weight cut-off) was
carefully inserted into the guide cannula. The probe was secured
to the guide cannula using a screw. The tip of the dialysis probe
protruded 2 mm below the distal end of the guide cannula. The
probes had an in vitro recovery of 10–12% for dopamine. The inlet
and outlet of the probe were connected to a swivel that allowed the
rat to move freely inside the microdialysis cage. The dialysis probe
was perfused at a rate of 2.0 ml/min with Modified Ringer solution
(147 mM NaCl, 4 mM KCl, 1.1 mM CaCl2.2H2O and 1.1 mM
MgCl2.6H2O, dissolved in ultra pure water, pH 7.4). The outflow
was collected every 15 min in a tube containing 8 ml of 0.02 M
formic acid and kept at 280uC until analyzed. The samples were
manually injected into a high performance liquid chromatography
(HPLC) system. Dopamine was separated from the remaining
neurotransmitters by means of reversed phase, ion-paring liquid
chromatography using an Eicompak PP-ODS column (particle
size: 2 mm, 4.6 mm630mm) in combination with a mobile phase
(0.1 M phosphate buffer [NaH2PO4.2H2O : Na2HPO4.12H2O,
ratio 25:4], 2.0 mM sodium 1-decanesulphonate and 0.1 mM di-
sodium EDTA, dissolved in ultra pure water [.18 MV], pH 6.0)
containing 1% of methanol. The flow rate was 500 ml/min and the
system temperature was 25uC. The concentration of dopamine
was measured using electrochemical detection. The working
electrode was set at +400 mV against a silver/silver-chloride
reference electrode. The accuracy of measurement was within
1.3% and the detection limit was about 30fg per sample. The
system was calibrated using a standard dopamine solution before
each measurement. On the experimental day, food was removed 1
hr before start of the experiment and during the remainder of the
experiment. A stable baseline level of dopamine (610%) was
reached at 4 hr after insertion of the probe [49,71], followed by the
collection of 3 basal samples. Average basal dopamine levels are
expressed as pg dopamine in a 15 min dialysate sample.
Microdialysis histology
At the end of the experiment, rats were given an overdose of
sodium-pentobarbital (250 mg/kg, intraperitoneal) and were
intracardially perfused with 60 ml 4% paraformaldehyde solution.
Vibratome sections (35 mm) were cut to determine the correct
location of the microdialysis probe.
Data analysis
All data are expressed as mean 6 S.E.M. Meal pattern
characteristics (Figures 1A-I) were analyzed by repeated-measures
ANOVA that included the between-subject factor of genotype and the
within-subjects factor of time. If an effect was observed, the ANOVA
was followed by an unpaired Students’ t-test analysis. In addition,
figs. 1B-G were also analyzed by an ANCOVA at each
experimental time point with body weight as covariate. As we were
interested in a parameter that only showed a genotype effect at PND
40, repeated measured ANCOVAs could not be used for this
analysis. Acute hyperphagia and hypophagia (Figs. 2A and B) were
analyzed by repeated-measures ANOVA with a special contrast to
investigate if the intake on the test day (HF day1 or SHP day1) was
different from the average intake of 5 preceding days (SHP days1–5
or HF days1–5). Elements of high-fat food-reinforced responding
(Figs. 3B-H) were analyzed by repeated-measures ANOVA. If an
effect was observed, the ANOVA was followed by an unpaired
Students’ t-test analysis. Body weight and food intake during chronic
aCSF or NEI administration were analyzed by repeated-measures
ANOVA with genotype and treatment as between-subject factors and
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the within-subjects factor of time, with a Bonferroni post-hoc
correction for multiple comparisons. For the AcbSh infusions we
used a mixed experimental design that included the between-subject
factors of genotype and treatment and the within-subjects factor of time,
with a Bonferroni post-hoc correction for multiple comparisons.
Within time-point data were analyzed using an unpaired Students’
t-test. The effect of GBR12909 on dopamine release was analyzed
using a 2-way ANOVA with between-subject factors of genotype and
treatment. All other data were analyzed using an unpaired Students’ t-
test. All data were analyzed using a commercially available statistical
program (SPSS for Macintosh, version 16.0). The null hypothesis
was rejected at the 0.05 level.
Supporting Information
Table S1 Statistical results for the meal structure
analysis.
(TIF)
Table S2 Gene name, gene ID, and forward and reverse
primer sequences for qPCR analysis of NAc gene
expression.
(TIF)
Acknowledgments
We gratefully acknowledge Sabine Grol, Delphi Coppens, and Wendy de
Vries for initial animal studies and data analysis, Mieneke Luijendijk for
initial meal pattern analysis, Rea van Rozen for help with the
autoradiographic DAT assay, and Yvar van Mourik, Franc¸ois Hogen-
boom, and Joost Wiskerke for excellent animal care, tissue isolation, and
technical assistance.
Author Contributions
Conceived and designed the experiments: JDM SELF MMMV RMS JRH
ANMS RAHA RJD TJDV EC. Performed the experiments: JDM SELF
PWT AA-M RB DS MMMV RMS. Analyzed the data: JDM SELF DS
MMMV RMS. Contributed reagents/materials/analysis tools: JRH
ANMS RAHA RJD TJDV EC. Wrote the paper: JDM SELF MMMV
RMS JRH TJDV EC.
References
1. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, et al. (1992) The melanin-
concentrating hormone system of the rat brain: an immuno- and hybridization
histochemical characterization. J Comp Neurol 319: 218–245.
2. Sita LV, Elias CF, Bittencourt JC (2007) Connectivity pattern suggests that
incerto-hypothalamic area belongs to the medial hypothalamic system.
Neuroscience 148: 949–969.
3. Zamir N, Skofitsch G, Jacobowitz DM (1986) Distribution of immunoreactive
melanin-concentrating hormone in the central nervous system of the rat. Brain
Res 373: 240–245.
4. Nahon JL, Presse F, Bittencourt JC, Sawchenko PE, Vale W (1989) The rat
melanin-concentrating hormone messenger ribonucleic acid encodes multiple
putative neuropeptides coexpressed in the dorsolateral hypothalamus. Endocri-
nology 125: 2056–2065.
5. Silva JP, von Meyenn F, Howell J, Thorens B, Wolfrum C, et al. (2009)
Regulation of adaptive behaviour during fasting by hypothalamic Foxa2. Nature
462: 646–650.
6. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, et al. (1996) A
role for melanin-concentrating hormone in the central regulation of feeding
behaviour. Nature 380: 243–247.
7. Alon T, Friedman JM (2006) Late-onset leanness in mice with targeted ablation
of melanin concentrating hormone neurons. J Neurosci 26: 389–397.
8. Mul JD, Yi CX, van den Berg SA, Ruiter M, Toonen PW, et al. (2010) Pmch
expression during early development is critical for normal energy homeostasis.
Am J Physiol Endocrinol Metab 298: E477–488.
9. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E (1998) Mice
lacking melanin-concentrating hormone are hypophagic and lean. Nature 396:
670–674.
10. Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, et al. (2001)
Melanin-concentrating hormone overexpression in transgenic mice leads to
obesity and insulin resistance. J Clin Invest 107: 379–386.
11. Rossi M, Choi SJ, O’Shea D, Miyoshi T, Ghatei MA, et al. (1997) Melanin-
concentrating hormone acutely stimulates feeding, but chronic administration
has no effect on body weight. Endocrinology 138: 351–355.
12. Della-Zuana O, Presse F, Ortola C, Duhault J, Nahon JL, et al. (2002) Acute
and chronic administration of melanin-concentrating hormone enhances food
intake and body weight in Wistar and Sprague-Dawley rats. Int J Obes Relat
Metab Disord 26: 1289–1295.
13. Gomori A, Ishihara A, Ito M, Mashiko S, Matsushita H, et al. (2003) Chronic
intracerebroventricular infusion of MCH causes obesity in mice. Melanin-
concentrating hormone. Am J Physiol Endocrinol Metab 284: E583–
588.
14. Ito M, Gomori A, Ishihara A, Oda Z, Mashiko S, et al. (2003) Characterization
of MCH-mediated obesity in mice. Am J Physiol Endocrinol Metab 284:
E940–945.
15. Guesdon B, Paradis E, Samson P, Richard D (2009) Effects of intracerebroven-
tricular and intra-accumbens melanin-concentrating hormone agonism on food
intake and energy expenditure. Am J Physiol Regul Integr Comp Physiol 296:
R469–475.
16. Morens C, Norregaard P, Receveur JM, van Dijk G, Scheurink AJ (2005) Effects
of MCH and a MCH1-receptor antagonist on (palatable) food and water intake.
Brain Res 1062: 32–38.
17. Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, et al. (1999)
Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-
coupled receptor SLC-1. Nature 400: 261–265.
18. Lembo PM, Grazzini E, Cao J, Hubatsch DA, Pelletier M, et al. (1999) The
receptor for the orexigenic peptide melanin-concentrating hormone is a G-
protein-coupled receptor. Nat Cell Biol 1: 267–271.
19. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, et al. (1999) Molecular
characterization of the melanin-concentrating-hormone receptor. Nature 400:
265–269.
20. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, et al. (2000) The
distribution of the mRNA and protein products of the melanin-concentrating
hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat.
Eur J Neurosci 12: 1194–1216.
21. Georgescu D, Sears RM, Hommel JD, Barrot M, Bolanos CA, et al. (2005) The
hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus
accumbens to modulate feeding behavior and forced-swim performance.
J Neurosci 25: 2933–2940.
22. Chen Y, Hu C, Hsu CK, Zhang Q, Bi C, et al. (2002) Targeted disruption of the
melanin-concentrating hormone receptor-1 results in hyperphagia and resistance
to diet-induced obesity. Endocrinology 143: 2469–2477.
23. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, et al. (2002)
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive,
and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A 99:
3240–3245.
24. Ito M, Ishihara A, Gomori A, Matsushita H, Metzger JM, et al. (2009)
Mechanism of the anti-obesity effects induced by a novel Melanin-concentrating
hormone 1-receptor antagonist in mice. Br J Pharmacol.
25. Shearman LP, Camacho RE, Sloan Stribling D, Zhou D, Bednarek MA, et al.
(2003) Chronic MCH-1 receptor modulation alters appetite, body weight and
adiposity in rats. Eur J Pharmacol 475: 37–47.
26. Mashiko S, Ishihara A, Gomori A, Moriya R, Ito M, et al. (2005) Antiobesity
effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced
obese mice. Endocrinology 146: 3080–3086.
27. Nair SG, Adams-Deutsch T, Pickens CL, Smith DG, Shaham Y (2009) Effects of
the MCH1 receptor antagonist SNAP 94847 on high-fat food-reinforced
operant responding and reinstatement of food seeking in rats. Psychopharma-
cology (Berl).
28. Smith DG, Tzavara ET, Shaw J, Luecke S, Wade M, et al. (2005) Mesolimbic
dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-
deficient mice. J Neurosci 25: 914–922.
29. Pissios P, Frank L, Kennedy AR, Porter DR, Marino FE, et al. (2008)
Dysregulation of the mesolimbic dopamine system and reward in MCH-/- mice.
Biol Psychiatry 64: 184–191.
30. Tyhon A, Adamantidis A, Foidart A, Grisar T, Lakaye B, et al. (2006) Mice
lacking the melanin-concentrating hormone receptor-1 exhibit an atypical
psychomotor susceptibility to cocaine and no conditioned cocaine response.
Behav Brain Res 173: 94–103.
31. Tyhon A, Lakaye B, Grisar T, Tirelli E (2008) Deletion of Melanin-
Concentrating Hormone Receptor-1 gene accentuates D-amphetamine-induced
psychomotor activation but neither the subsequent development of sensitization
nor the expression of conditioned activity in mice. Pharmacol Biochem Behav
88: 446–455.
32. Chung S, Hopf FW, Nagasaki H, Li CY, Belluzzi JD, et al. (2009) The melanin-
concentrating hormone systemmodulates cocaine reward. Proc Natl Acad Sci U S A.
33. Stratford TR, Kelley AE (1997) GABA in the nucleus accumbens shell
participates in the central regulation of feeding behavior. J Neurosci 17:
4434–4440.
MCH, Motivation, and Feeding
PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e19600
34. Stratford TR, Kelley AE (1999) Evidence of a functional relationship between
the nucleus accumbens shell and lateral hypothalamus subserving the control of
feeding behavior. J Neurosci 19: 11040–11048.
35. Stratford TR, Swanson CJ, Kelley A (1998) Specific changes in food intake
elicited by blockade or activation of glutamate receptors in the nucleus
accumbens shell. Behav Brain Res 93: 43–50.
36. Maldonado-Irizarry CS, Swanson CJ, Kelley AE (1995) Glutamate receptors in
the nucleus accumbens shell control feeding behavior via the lateral
hypothalamus. J Neurosci 15: 6779–6788.
37. Reynolds SM, Berridge KC (2001) Fear and feeding in the nucleus accumbens
shell: rostrocaudal segregation of GABA-elicited defensive behavior versus eating
behavior. J Neurosci 21: 3261–3270.
38. Sears RM, Liu RJ, Narayanan NS, Sharf R, Yeckel MF, et al. (2010) Regulation
of nucleus accumbens activity by the hypothalamic neuropeptide melanin-
concentrating hormone. J Neurosci 30: 8263–8273.
39. Kelley AE (2004) Ventral striatal control of appetitive motivation: role in
ingestive behavior and reward-related learning. Neurosci Biobehav Rev 27:
765–776.
40. Ghitza UE, Gray SM, Epstein DH, Rice KC, Shaham Y (2006) The anxiogenic
drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of
CRF1 receptors. Neuropsychopharmacology 31: 2188–2196.
41. Ghitza UE, Nair SG, Golden SA, Gray SM, Uejima JL, et al. (2007) Peptide
YY3-36 decreases reinstatement of high-fat food seeking during dieting in a rat
relapse model. J Neurosci 27: 11522–11532.
42. Nair SG, Golden SA, Shaham Y (2008) Differential effects of the hypocretin 1
receptor antagonist SB 334867 on high-fat food self-administration and
reinstatement of food seeking in rats. Br J Pharmacol 154: 406–416.
43. Nair SG, Gray SM, Ghitza UE (2006) Role of food type in yohimbine- and
pellet-priming-induced reinstatement of food seeking. Physiol Behav 88:
559–566.
44. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-
administration studies in rats: a method to evaluate reinforcing efficacy.
J Neurosci Methods 66: 1–11.
45. Bittencourt J, Celis ME (2008) Anatomy, function and regulation of
neuropeptide EI (NEI). Peptides 29: 1441–1450.
46. Edwards RH (1992) The transport of neurotransmitters into synaptic vesicles.
Curr Opin Neurobiol 2: 586–594.
47. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct
pharmacological properties and distribution in neurons and endocrine cells of
two isoforms of the human vesicular monoamine transporter. Proc Natl Acad
Sci U S A 93: 5166–5171.
48. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, et al. (1995) Differential
expression of two vesicular monoamine transporters. J Neurosci 15: 6179–6188.
49. Verheij MM, de Mulder EL, De Leonibus E, van Loo KM, Cools AR (2008)
Rats that differentially respond to cocaine differ in their dopaminergic storage
capacity of the nucleus accumbens. J Neurochem 105: 2122–2133.
50. Holtje M, von Jagow B, Pahner I, Lautenschlager M, Hortnagl H, et al. (2000)
The neuronal monoamine transporter VMAT2 is regulated by the trimeric
GTPase Go(2). J Neurosci 20: 2131–2141.
51. Pissios P, Trombly DJ, Tzameli I, Maratos-Flier E (2003) Melanin-concentrating
hormone receptor 1 activates extracellular signal-regulated kinase and synergizes
with G(s)-coupled pathways. Endocrinology 144: 3514–3523.
52. Bachner D, Kreienkamp H, Weise C, Buck F, Richter D (1999) Identification of
melanin concentrating hormone (MCH) as the natural ligand for the orphan
somatostatin-like receptor 1 (SLC-1). FEBS Lett 457: 522–524.
53. Hawes BE, Kil E, Green B, O’Neill K, Fried S, et al. (2000) The melanin-
concentrating hormone receptor couples to multiple G proteins to activate
diverse intracellular signaling pathways. Endocrinology 141: 4524–4532.
54. Gao XB, van den Pol AN (2001) Melanin concentrating hormone depresses
synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus.
J Physiol 533: 237–252.
55. Greengard P, Valtorta F, Czernik AJ, Benfenati F (1993) Synaptic vesicle
phosphoproteins and regulation of synaptic function. Science 259: 780–785.
56. Kowalski TJ, Farley C, Cohen-Williams ME, Varty G, Spar BD (2004) Melanin-
concentrating hormone-1 receptor antagonism decreases feeding by reducing
meal size. Eur J Pharmacol 497: 41–47.
57. Bittencourt JC, Elias CF (1998) Melanin-concentrating hormone and neuro-
peptide EI projections from the lateral hypothalamic area and zona incerta to
the medial septal nucleus and spinal cord: a study using multiple neuronal
tracers. Brain Res 805: 1–19.
58. Zheng H, Patterson LM, Morrison C, Banfield BW, Randall JA, et al. (2005)
Melanin concentrating hormone innervation of caudal brainstem areas involved
in gastrointestinal functions and energy balance. Neuroscience 135: 611–625.
59. Abbott CR, Kennedy AR, Wren AM, Rossi M, Murphy KG, et al. (2003)
Identification of hypothalamic nuclei involved in the orexigenic effect of
melanin-concentrating hormone. Endocrinology 144: 3943–3949.
60. Moran TH, Ameglio PJ, Schwartz GJ, McHugh PR (1992) Blockade of type A,
not type B, CCK receptors attenuates satiety actions of exogenous and
endogenous CCK. Am J Physiol 262: R46–50.
61. Hodos W (1961) Progressive ratio as a measure of reward strength. Science 134:
943–944.
62. Hodos W, Kalman G (1963) Effects of increment size and reinforcer volume on
progressive ratio performance. J Exp Anal Behav 6: 387–392.
63. Saper CB, Chou TC, Elmquist JK (2002) The need to feed: homeostatic and
hedonic control of eating. Neuron 36: 199–211.
64. Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic
orexin neurons in reward seeking. Nature 437: 556–559.
65. Leinninger GM, Jo YH, Leshan RL, Louis GW, Yang H, et al. (2009) Leptin
acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the
mesolimbic dopamine system and suppress feeding. Cell Metab 10: 89–98.
66. Inoue K, Valdez GR, Reyes TM, Reinhardt LE, Tabarin A, et al. (2003)
Human urocortin II, a selective agonist for the type 2 corticotropin-releasing
factor receptor, decreases feeding and drinking in the rat. J Pharmacol Exp Ther
305: 385–393.
67. Tiesjema B, Adan RA, Luijendijk MC, Kalsbeek A, la Fleur SE (2007)
Differential effects of recombinant adeno-associated virus-mediated neuropep-
tide Y overexpression in the hypothalamic paraventricular nucleus and lateral
hypothalamus on feeding behavior. J Neurosci 27: 14139–14146.
68. Panksepp J (1973) Reanalysis of feeding patterns in the rat. J Comp Physiol
Psychol 82: 78–94.
69. Redmond DE Jr., Huang YH (1979) Current concepts. II. New evidence for a
locus coeruleus-norepinephrine connection with anxiety. Life Sci 25:
2149–2162.
70. Schoffelmeer AN, Rice KC, Jacobson AE, Van Gelderen JG, Hogenboom F,
et al. (1988) Mu-, delta- and kappa-opioid receptor-mediated inhibition of
neurotransmitter release and adenylate cyclase activity in rat brain slices: studies
with fentanyl isothiocyanate. Eur J Pharmacol 154: 169–178.
71. Verheij MM, Cools AR (2007) Differential contribution of storage pools to the
extracellular amount of accumbal dopamine in high and low responders to
novelty: effects of reserpine. J Neurochem 100: 810–821.
72. Paxinos G, Watson C (2005) The Rat Brain in Stereotaxic Coordinates. New
York: Academic Press.
MCH, Motivation, and Feeding
PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e19600
